Psychopharmacology of Attention-Deficit Hyperactivity Disorder: Effects and Side Effects.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing mechanisms, effects, and side effects without systematic review methodology.
PubMed 26601963 · doi:10.2174/1381612822666151124235816
What was done
This paper reviews the psychopharmacology of attention-deficit hyperactivity disorder (ADHD), examining the mechanisms of action, clinical effects, and side effect profiles of common medications including stimulants (such as methylphenidate and amphetamines), atomoxetine, bupropion, antidepressants, clonidine, and melatonin.
What was found
The abstract provides no quantitative data, effect sizes, or statistical figures. It reports qualitatively that stimulants act via dopamine and norepinephrine release in the central nervous system, that methylphenidate significantly reduces ADHD symptoms across home and school environments while improving social skills, and that methylphenidate is generally safe and showed no cardiac side effects in healthy children.
Why it matters
It provides a broad overview of standard first-line and alternative pharmacotherapies for managing pediatric ADHD symptoms and their associated side effect considerations.
Limits
The abstract describes a narrative review rather than a systematic review or meta-analysis. It provides no search criteria, study selection details, sample sizes, or numerical estimates of efficacy and adverse event rates.
Cited by
- supports Prescription stimulants such as Adderall and Vyvanse are amphetamines that primarily release catecholamines, mainly dopamine and epinephrine.